HYFT - NASDAQ
MindWalk Holdings Corp.
$1.82
+6.1%MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
At a Glance
Live Snapshothyft
Cash and Short Term Investments
Last Annual Value
10.66M
3-Year CAGR
-29%
5-Year CAGR
33%
10-Year CAGR
75%
MindWalk Holdings Corp. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 MindWalk Holdings Corp. NASDAQ:HYFT | 10.66M | 8.8% | -23.9% | 34.4% | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 40.78M | -18.4% | -17.5% | N/A | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | 41.27M | 62.0% | 20.0% | N/A | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 44.79M | -37.4% | -34.2% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 81.54M | 34.5% | -3.1% | N/A | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 78.69M | -7.1% | -6.1% | 0.9% | |
 Clene Inc. NASDAQ:CLNN | 5.19M | -47.1% | -36.5% | N/A | |
 CervoMed Inc. NASDAQ:CRVO | 38.92M | 70.9% | 0.8% | 38.0% | |
 Lite Strategy, Inc. NASDAQ:LITS | 18.01M | -43.7% | -34.8% | N/A | |
 XBiotech Inc. NASDAQ:XBIT | 125.55M | -14.4% | -11.9% | 13.8% | |
 ImageneBio Inc NASDAQ:IMA | 75.78M | -24.4% | -20.1% | N/A |
MindWalk Holdings Corp. Fair Value Envelope
Related Guides
Continue your HYFT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.